Skip to main content
. 2021 Apr 1:cwab021. doi: 10.1093/glycob/cwab021

Table IV.

Parameters for assessing the suitability of the compound for being used as a drug predicted by QikProp

Compound Mw P oct/W Oral absorption/% # Of violations of rule of 5 # Of violations of rule of 3
BAS 00380341 674.75 2.6 12.1 3 2
LAS 52112123 646.74 3.8 57.6 2 2
BDG 34018174 473.53 0.7 36.4 0 1
ASN 03798802 713.86 2.7 37.1 2 2
BDG 33898632 542.58 --1.3 5.8 3 1
BAS 00060295 592.55 --0.8 1.1 3 2
LAS 33898721 713.78 0.0 7.2 3 2